PSILOCYBIN:

A naturally occurring psychedelic compound with promise as a psychiatric intervention for depression, PTSD, OCD, anorexia nervosa and addictions to alcohol, stimulants and tobacco.

Its Schedule 1 status under the Misuse of Drugs Regulations 2001 is hindering research.

11 Clinical trials have been completed since 2006.

52 Clinical trials are ongoing world wide...

...but <10% are taking place in the UK with 70% in North America.

WHY HINDER RESEARCH INTO MENTAL HEALTH?

1

✓ **Significant** decrease in depressive symptoms for up to 6 months (Carhart-Harris et al., 2016)

✓ **Significant** decreases in anxiety and **depression** for 6.5 months (Ross et al., 2016)

✓ **80% smoking abstinence** at 6 months (Johnson et al., 2014)

2

4 to 1 Public Support for a change in the law to facilitate UK research.

3

6570 suicides in the UK in 2018.

- Psilocybin is **currently more controlled than heroin. WHY?**
- With the exception of Esketamine there have been no new treatments for depression in over 30 years.

2

RESEARCH IS BEING HINDERED

Published scientific articles (y-axis: 0, 5, 10, 15, 20, 25)

UN Single Convention on Psychotropic Substances 1971

x-axis: 1959 1969 1979 1989 1999 2009

4

In 2018 the US FDA gave psilocybin 'Breakthrough Therapy' status awarding researchers...

$4M USD ...in Federal grants.

The Australian TGA have awarded...

**$15M AUD** ...in Government grants towards research into psilocybin and MDMA.

50+ ...publicly listed psychedelics companies listed across a number of exchanges, including the NYSE and NASDAQ with combined market caps exceeding...

$6 Billion USD

Yet no psychedelic companies are listed on the London Stock Exchange.

Psychedelic medicines market size set to grow to **$10 Billion USD by 2027**

WHY IS THE UK BEHIND?

5

6

1 - Number of registered clinical trials on clinicaltrials.gov, clinicaltrialsregister.eu, australianclinicaltrials.gov.au as of 2/11/2021.
2 - Medicinal Use of Psilocybin: Reducing Restrictions on Research and Treatment. Rucker et al., 2020.
3 - Public Attitudes to Psilocybin-Assisted Therapy. Drug Science and Psilonautica. 2021.   5 - Psilocybinalpha.com
4 - pubmed.ncbi.nlm.nih.gov
6 - Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027. prnewswire.com